Atara Biotherapeutics, Inc. (ATRA) Balance Sheet
ATRA balance sheet, 2025
December 31, 2025 · U.S. dollars$20.2M assets = $58.7M liabilities + −$38.5M equity
Liabilities exceed assets: shareholders’ equity is negative (−$38.5M).
Both columns are drawn to the same scale: what ATRA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ATRA financial health
Descriptive bands, not a rating. Fiscal 2025.
ATRA balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $263.9M2016 | $20.2M2025 | −24.8%/yr | |
| Total liabilities | $10.2M2016 | $58.7M2025 | +21.5%/yr | |
| Shareholders’ equity | $253.7M2016 | −$38.5M2025 | — | |
| Cash & short-term investments | $255.7M2016 | $8.5M2025 | −31.5%/yr | |
| Total debt | $500,0002017 | $52.8M2025 | +79.0%/yr | |
| Net cash (debt) | $165.6M2017 | −$44.3M2025 | −$209.9M | |
| Working capital | $250.9M2016 | −$2.7M2025 | −$253.6M | |
| Book value per share | $141.682019 | −$3.032025 | — | |
| Current ratio | 26.932016 | 0.822025 | −26.11 | |
| Debt / equity | 0.002017 | 0.572022 | +0.56 | |
| Shares outstanding | 2.1M2019 | 12.7M2025 | +35.5%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ATRA assets
ATRA liabilities and equity
ATRA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ATRA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $8.5M | $42.5M | $51.7M | $242.8M | $371.1M | $500.7M | $259.1M | $309.6M | $166.1M | $255.7M |
| Cash & equivalents | $8.5M | $25.0M | $25.8M | $92.9M | $106.1M | $200.4M | $74.3M | $60.7M | $79.2M | $48.0M |
| Short-term investments | $0 | $17.5M | $25.9M | $149.9M | $265.0M | $300.3M | $184.8M | $248.9M | $86.9M | $207.7M |
| Receivables | $1.3M | $1.5M | $34.1M | $40.2M | $986,000 | $1.2M | $0 | $0 | $0 | $0 |
| Inventory | $0 | $10.7M | $9.7M | $1.6M | $1 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $2.5M | $10.3M | $6.3M | $10.5M | $12.6M | $21.4M | $13.9M | $11.9M | $6.1M | $4.9M |
| Total current assets | $12.2M | $64.9M | $101.9M | $295.1M | $384.6M | $523.3M | $273.0M | $321.5M | $172.2M | $260.6M |
| Property, plant & equipment (net) | $7.1M | $41.1M | $58.8M | $74.3M | $79.9M | $62.8M | $68.2M | $68.6M | $44.1M | $3.3M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $886,000 | $3.1M | $4.8M | $7.0M | $3.6M | $2.0M | $1.8M | $1.8M | $1.5M | $102,000 |
| Total assets | $20.2M | $109.1M | $165.5M | $376.4M | $468.1M | $588.1M | $342.9M | $391.8M | $217.8M | $263.9M |
| Liabilities | ||||||||||
| Accounts payable | $127,000 | $4.4M | $3.7M | $6.9M | $17.4M | $7.1M | $8.0M | $3.7M | $14.7M | $2.8M |
| Short-term debt | $10.8M | $13.9M | $12.2M | $13.6M | $2.8M | $2.0M | $1.6M | $587,000 | $500,000 | — |
| Deferred revenue | $716,000 | $95.1M | $77.8M | $8.0M | $40.8M | $33.5M | $21.5M | −$490,000 | −$500,000 | — |
| Total current liabilities | $14.9M | $134.6M | $142.2M | $78.9M | $105.8M | $82.9M | $36.7M | $40.0M | $27.6M | $9.7M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $244,000 | $0 | $10.5M | $0 |
| Lease obligations | $10.4M | $43.8M | $57.9M | $71.7M | $25.5M | $15.0M | $15.7M | — | — | — |
| Other long-term liabilities | $43.8M | $71.8M | $122.5M | $170.9M | $82.7M | $42.9M | $15.2M | $13.0M | $1.8M | $503,000 |
| Total liabilities | $58.7M | $206.4M | $264.7M | $249.8M | $188.5M | $125.8M | $52.2M | $53.0M | $39.9M | $10.2M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $11,000 | $10,000 | $9,000 | $8,000 | $6,000 | $5,000 | $3,000 | $3,000 |
| Retained earnings (deficit) | −$2.02B | −$2.05B | −$1.97B | −$1.69B | −$1.46B | −$1.12B | −$818.0M | −$527.3M | −$296.6M | −$177.2M |
| Treasury stock | — | — | — | — | — | — | — | — | $0 | $0 |
| Accumulated other comprehensive income | $1,000 | $8,000 | −$204,000 | −$2.1M | −$368,000 | $296,000 | $220,000 | −$340,000 | −$151,000 | −$183,000 |
| Minority interest | — | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | −$38.5M | −$97.3M | −$99.2M | $126.6M | $279.6M | $462.3M | $290.8M | $338.9M | $177.9M | $253.7M |
| Key figures | ||||||||||
| Total debt | $52.8M | $43.8M | $57.9M | $71.7M | $28.3M | $15.0M | $15.7M | $738,000 | $500,000 | — |
| Net cash (debt) | −$44.3M | −$1.3M | −$6.1M | $171.1M | $342.8M | $485.6M | $243.4M | $308.9M | $165.6M | — |
| Working capital | −$2.7M | −$69.7M | −$40.4M | $216.2M | $278.8M | $440.4M | $236.2M | $281.5M | $144.5M | $250.9M |
| Tangible book value | −$38.5M | −$97.3M | −$99.2M | $126.6M | $279.6M | $462.3M | $290.8M | $338.9M | $177.9M | $253.7M |
| Book value per share | −$3.03 | −$12.99 | −$23.42 | $31.04 | $74.63 | $156.25 | $141.68 | — | — | — |
| Shares outstanding | 12.7M | 7.5M | 4.2M | 4.1M | 3.7M | 3.0M | 2.1M | — | — | — |
| Current ratio | 0.82 | 0.48 | 0.72 | 3.74 | 3.64 | 6.31 | 7.43 | 8.04 | 6.23 | 26.93 |
| Quick ratio | 0.65 | 0.33 | 0.60 | 3.59 | 3.52 | 6.05 | 7.05 | 7.74 | 6.01 | 26.43 |
| Debt / equity | — | — | — | 0.57 | 0.10 | 0.03 | 0.05 | 0.00 | 0.00 | — |
| Equity / assets | −190.3% | −89.2% | −60.0% | 33.6% | 59.7% | 78.6% | 84.8% | 86.5% | 81.7% | 96.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $9.9M | $8.4M | $8.5M | $13.7M | $22.3M | $13.8M | $42.5M | $67.2M | $35.3M | $46.2M | $51.7M | $102.4M |
| Cash & equivalents | $3.2M | $8.4M | $8.5M | $5.7M | $16.9M | $13.8M | $25.0M | $46.5M | $31.3M | $35.1M | $25.8M | $64.8M |
| Short-term investments | $6.7M | — | $0 | $8.0M | $5.4M | $0 | $17.5M | $20.7M | $4.0M | $11.2M | $25.9M | $37.6M |
| Receivables | $318,000 | $0 | $1.3M | $1.9M | $0 | $8.9M | $1.5M | $1.3M | $2.4M | $35.8M | $34.1M | $163,000 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $10.7M | $14.0M | $18.7M | $16.1M | $9.7M | $6.6M |
| Other current assets | $3.3M | $3.8M | $2.5M | $2.8M | $2.4M | $4.5M | $10.3M | $9.4M | $5.9M | $8.3M | $6.3M | $9.5M |
| Total current assets | $13.5M | $12.2M | $12.2M | $18.4M | $24.8M | $27.2M | $64.9M | $91.9M | $62.4M | $106.4M | $101.9M | $118.7M |
| Property, plant & equipment (net) | $6.7M | $6.9M | $7.1M | $10.9M | $11.2M | $32.0M | $41.1M | $47.5M | $51.3M | $55.0M | $58.8M | $63.8M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $765,000 | $890,000 | $886,000 | $881,000 | $927,000 | $2.8M | $3.1M | $3.4M | $3.6M | $3.9M | $4.8M | $6.3M |
| Total assets | $21.0M | $20.0M | $20.2M | $30.2M | $36.9M | $62.0M | $109.1M | $142.7M | $117.3M | $165.3M | $165.5M | $188.8M |
| Liabilities | ||||||||||||
| Accounts payable | $824,000 | $637,000 | $127,000 | $318,000 | $1.8M | $1.4M | $4.4M | $2.1M | $5.3M | $2.9M | $3.7M | $6.5M |
| Short-term debt | $1.1M | $1.0M | $10.8M | $11.6M | $2.2M | $13.9M | $13.9M | $14.7M | $14.0M | $14.0M | $12.2M | $13.3M |
| Deferred revenue | $775,000 | $684,000 | $716,000 | $1.0M | $1.6M | $16.0M | $95.1M | $116.3M | $107.6M | $123.2M | $77.8M | $11.6M |
| Total current liabilities | $6.8M | $5.6M | $14.9M | $18.1M | $14.6M | $47.9M | $134.6M | $156.0M | $148.3M | $180.7M | $142.2M | $79.1M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $9.9M | $10.1M | $10.4M | $17.0M | $17.7M | $40.6M | $43.8M | $49.9M | $52.7M | $56.2M | $57.9M | $61.8M |
| Other long-term liabilities | $51.2M | $51.7M | $43.8M | $48.7M | $57.4M | $69.2M | $71.8M | $77.3M | $79.9M | $82.9M | $122.5M | $160.5M |
| Total liabilities | $58.0M | $57.3M | $58.7M | $66.8M | $71.9M | $117.1M | $206.4M | $233.2M | $228.2M | $263.6M | $264.7M | $239.6M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | — | $12,000 | $11,000 | $10,000 |
| Retained earnings (deficit) | −$2.03B | −$2.03B | −$2.02B | −$2.02B | −$2.01B | −$2.02B | −$2.05B | −$2.04B | −$2.02B | −$2.00B | −$1.97B | −$1.91B |
| Accumulated other comprehensive income | −$2,000 | — | $1,000 | $2,000 | — | $0 | $8,000 | $22,000 | −$14,000 | −$55,000 | −$204,000 | −$571,000 |
| Total shareholders' equity | −$37.0M | −$37.3M | −$38.5M | −$36.6M | −$35.0M | −$55.1M | −$97.3M | −$90.5M | −$110.9M | −$98.3M | −$99.2M | −$50.8M |
| Key figures | ||||||||||||
| Total debt | $9.9M | $10.1M | $52.8M | $58.6M | $17.7M | $40.6M | $43.8M | $49.9M | $52.7M | $56.2M | $57.9M | $61.8M |
| Net cash (debt) | −$6,000 | −$1.7M | −$44.3M | −$44.9M | $4.7M | −$26.8M | −$1.3M | $17.3M | −$17.4M | −$10.0M | −$6.1M | $40.6M |
| Working capital | $6.7M | $6.5M | −$2.7M | $375,000 | $10.2M | −$20.7M | −$69.7M | −$64.1M | −$85.9M | −$74.3M | −$40.4M | $39.6M |
| Tangible book value | −$37.0M | −$37.3M | −$38.5M | −$36.6M | −$35.0M | −$55.1M | −$97.3M | −$90.5M | −$110.9M | −$98.3M | −$99.2M | −$50.8M |
| Book value per share | −$2.46 | −$2.65 | −$3.03 | −$2.70 | −$2.85 | −$5.08 | −$9.10 | −$12.13 | −$18.05 | −$17.48 | −$22.94 | −$11.94 |
| Shares outstanding | 15.0M | 14.1M | 12.7M | 13.6M | 12.3M | 10.9M | 10.7M | 7.5M | 6.1M | 5.6M | 4.3M | 4.3M |
| Current ratio | 1.98 | 2.16 | 0.82 | 1.02 | 1.70 | 0.57 | 0.48 | 0.59 | 0.42 | 0.59 | 0.72 | 1.50 |
| Quick ratio | 1.49 | 1.48 | 0.65 | 0.87 | 1.53 | 0.47 | 0.33 | 0.44 | 0.25 | 0.45 | 0.60 | 1.30 |
| Equity / assets | −176.0% | −186.6% | −190.3% | −121.4% | −95.0% | −88.8% | −89.2% | −63.4% | −94.5% | −59.5% | −60.0% | −26.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 16, 2026); data from EODHD.
ATRA financial position
At the end of fiscal 2025 (December 31, 2025), Atara Biotherapeutics had total assets of $20.2 million (down 81.5% from a year earlier), total liabilities of $58.7 million and shareholders' equity of -$38.5 million. It held $8.5 million in cash and short-term investments against $52.8 million of debt, net debt of $44.3 million. Its current ratio was 0.82. In the latest quarter (ended June 30, 2026) total assets were $21.0 million and equity -$37.0 million.
Related: ATRA income statement, ATRA cash flow statement, ATRA key metrics. See the ATRA stock overview for the latest quote and news.
ATRA balance sheet FAQ
What are Atara Biotherapeutics's total assets?
Atara Biotherapeutics reported total assets of $20.2 million at the end of fiscal 2025 (December 31, 2025), compared with $109.1 million a year earlier.
How much debt does Atara Biotherapeutics have?
Atara Biotherapeutics had $52.8 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Atara Biotherapeutics have?
Atara Biotherapeutics held $8.5 million in cash and short-term investments at the end of fiscal 2025; with $52.8 million of debt that is net debt of $44.3 million.
What is Atara Biotherapeutics's book value?
Atara Biotherapeutics's shareholders' equity (book value) was -$38.5 million at the end of fiscal 2025, or −$3.03 per share.
What is Atara Biotherapeutics's current ratio?
Atara Biotherapeutics had current assets of $12.2 million and current liabilities of $14.9 million, a current ratio of 0.82 (current liabilities exceed current assets).